NCT05877222CompletedPhase 1
A Single-center, Open-label, Randomized, Crossover Phase 1 Trial to Investigate Bioequivalence Between 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants
Idorsia Pharmaceuticals Ltd.1 site in 1 country38 target enrollmentStarted: June 23, 2023Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Idorsia Pharmaceuticals Ltd.
- Enrollment
- 38
- Locations
- 1
- Primary Endpoint
- Cmax
Study Overview
Brief Summary
A Phase 1 trial to investigate bioequivalence between 5 × 10 mg tablets and 2 × 25 mg tablets of daridorexant in healthy male and female Japanese participants
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Signed informed consent in a language understandable to the participant prior to any trial-mandated procedure.
- •Healthy male and female participants aged between 18 and 65 years (inclusive) at Screening.
- •Body mass index of 18.5 to 29.9 kg/m2 (inclusive) at Screening.
- •Participant must be of native Japanese descent (all parents/grandparents of Japanese descent).
- •Participant must not have been away from Japan for more than 10 years (at Screening visit).
- •Participant's lifestyle should not have changed significantly since relocation from Japan.
Exclusion Criteria
- •Known hypersensitivity to daridorexant, or any of its excipients.
- •History of narcolepsy or cataplexy.
- •Clinically relevant findings on the physical examination at Screening.
- •Clinically relevant findings on 12-lead ECG, recorded after 5 min in a supine position at Screening.
- •Clinically relevant findings in clinical laboratory tests (hematology and clinical chemistry) at Screening.
- •Clinically relevant findings in systolic blood pressure, diastolic blood pressure, and pulse rate, measured on either arm, after 5 min in the supine position at Screening.
- •History of major medical or surgical disorders which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment (appendectomy and herniotomy allowed if performed > 12 weeks prior to administration of first study treatment, cholecystectomy not allowed).
- •Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
Arms & Interventions
Treatment A (5 × 10 mg daridorexant)
Experimental
Participants will receive a single oral dose of 5 × 10 mg daridorexant.
Intervention: Daridorexant 10 mg (Drug)
Treatment B (5 × 25 mg daridorexant)
Experimental
Participants will receive a single oral dose of 2 × 25 mg daridorexant.
Intervention: Daridorexant 25 mg (Drug)
Outcomes
Primary Outcomes
Cmax
Time Frame: Blood samples for PK analysis will be taken at several timepoints from treatment administration on Day 1 to Day 3 of Study periods 1 and 2 (Total duration: up to 4 days)
AUC0-t
Time Frame: Blood samples for PK analysis will be taken at several timepoints from treatment administration on Day 1 to Day 3 of Study periods 1 and 2 (Total duration: up to 4 days)
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted ConditionsHealthy ParticipantsNCT01619527Janssen R&D Ireland133
Completed
Phase 1
A Bioequivalence Study of TAK-536 Pediatric FormulationJapanese Healthy Adult MalesNCT02401464Takeda52
Completed
Phase 1
Phase1, Single Dose, Crossover Study to Determine BioequivalenceHealthyNCT00786240Pfizer37
Completed
Phase 1
Bioequivalence Between a Racecadotril Capsule and Film-Coated Tablet (FCT) to Treat Diarrhea in AdultsAntidiarrhealsNCT01302093McNeil AB40
Completed
Phase 1
Bioequivalence And Food Effect Study Of Bosutinib In Healthy SubjectsPhiladelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML)NCT01374139Pfizer88